Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash & Equivalents (2016 - 2025)

AC Immune has reported Cash & Equivalents over the past 11 years, most recently at $33.5 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 19.04% to $33.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.5 million through Dec 2025, down 19.04% year-over-year, with the annual reading at $33.5 million for FY2025, 19.04% down from the prior year.
  • Cash & Equivalents was $33.5 million for Q4 2025 at AC Immune, down from $34.7 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $89.2 million in Q4 2021 and troughed at $101925.1 in Q3 2021.
  • The 5-year median for Cash & Equivalents is $39.4 million (2024), against an average of $45.2 million.
  • Year-over-year, Cash & Equivalents tumbled 99.95% in 2021 and then soared 74650.25% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $89.2 million in 2021, then tumbled by 63.23% to $32.8 million in 2022, then soared by 169.9% to $88.5 million in 2023, then tumbled by 53.21% to $41.4 million in 2024, then dropped by 19.04% to $33.5 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Cash & Equivalents are $33.5 million (Q4 2025), $34.7 million (Q3 2025), and $43.8 million (Q2 2025).